Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sargos

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|January 11, 2024
Management of oligometastatic/metastatic sarcomas and place of local treatments with focus on modern radiotherapy approachesC Llacer-Moscardo, L Moureau-Zabotto, L Ollivier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]L Ferretti, M Gross-Goupil, P Sargos, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 10, 2018
Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendationsJ Langrand-Escure, R de Crevoisier, C Llagostera, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 15, 2020
[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]I Latorzeff, P Sargos, G Créhange, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 7, 2022
[DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology]G Ploussard, J-B Beauval, R Mathieu, et al.
Actas Urologicas Espanolas|April 4, 2024
Is trimodal therapy the current standard for muscle-invasive bladder cancer?M López Valcárcel, M Barrado Los Arcos, M Ferri Molina, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 1, 2022
[Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology]M Baboudjian, J-B Beauval, E Barret, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 31, 2023
Narrative review of PET/CT performances at biochemical recurrence in prostate cancer after radical prostatectomy and impact on patient disease management: Revue narrative à propos des performances de la TEP/TDM en cas de récidive biochimique après prostatectomie radicale dans le cancer de la prostate et impact sur la prise en charge des patientsM Lasserre, P Sargos, E Barret, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|October 12, 2023
Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancerI Latorzeff, A Camps-Maléa, S Supiot, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 18, 2022
French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistanceG Ploussard, G Roubaud, E Barret, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|January 11, 2024
Management of oligometastatic/metastatic sarcomas and place of local treatments with focus on modern radiotherapy approachesC Llacer-Moscardo, L Moureau-Zabotto, L Ollivier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]L Ferretti, M Gross-Goupil, P Sargos, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 10, 2018
Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendationsJ Langrand-Escure, R de Crevoisier, C Llagostera, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 15, 2020
[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]I Latorzeff, P Sargos, G Créhange, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 7, 2022
[DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology]G Ploussard, J-B Beauval, R Mathieu, et al.
Actas Urologicas Espanolas|April 4, 2024
Is trimodal therapy the current standard for muscle-invasive bladder cancer?M López Valcárcel, M Barrado Los Arcos, M Ferri Molina, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 1, 2022
[Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology]M Baboudjian, J-B Beauval, E Barret, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 31, 2023
Narrative review of PET/CT performances at biochemical recurrence in prostate cancer after radical prostatectomy and impact on patient disease management: Revue narrative à propos des performances de la TEP/TDM en cas de récidive biochimique après prostatectomie radicale dans le cancer de la prostate et impact sur la prise en charge des patientsM Lasserre, P Sargos, E Barret, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|October 12, 2023
Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancerI Latorzeff, A Camps-Maléa, S Supiot, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 18, 2022
French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistanceG Ploussard, G Roubaud, E Barret, et al.
Pageof 8